<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580433</url>
  </required_header>
  <id_info>
    <org_study_id>2020161820</org_study_id>
    <nct_id>NCT04580433</nct_id>
  </id_info>
  <brief_title>Time-restricted Feeding for Treating Polycystic Ovary Syndrome (PCOS)</brief_title>
  <acronym>PCOS</acronym>
  <official_title>Effects of 16:8 Time-restricted Feeding on the Endocrine and Metabolic Profile in Overweight Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chunzhu Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intermittent fasting is an increasingly popular diet pattern of alternating eating and&#xD;
      dieting.One particular form of intermittent fasting is the so-called time-restricted feeding&#xD;
      (TRF). TRF allows for ad libitum feeding within a large window of time each day, and does not&#xD;
      require any calorie counting. There is growing evidence that it can lose weight, reduce&#xD;
      insulin resistance and improve cardiometabolic health. Polycystic ovary syndrome (PCOS) is&#xD;
      the most common reproductive endocrine and metabolic disease affecting women of childbearing&#xD;
      age. PCOS shows anovulation or oligoovulation, hyperandrogenemia and ovarian polycystic&#xD;
      changes. Insulin resistance and obesity are common features of PCOS. Whether the TRF impacts&#xD;
      women with PCOS is still unknown due to the paucity of data in this area. To explore the&#xD;
      effects of TRF on the endocrine and metabolic profile in overweight women with PCOS, a 6-week&#xD;
      single-arm trial, divided into 2 consecutive periods: (1) 1-week baseline period; and (2)&#xD;
      5-week TRF period, will be implemented.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Actual">January 16, 2021</completion_date>
  <primary_completion_date type="Actual">January 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Will be assessed by homeostasis model assessment-insulin resistance (HOMA-IR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sex hormone-binding globulin (nmol/L)</measure>
    <time_frame>5-week intervention period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index (BMI) (kg/m^2)</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Weight (kg) and height (m) will be combined to report BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Waist-to-Hip Ratio (WHR)</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Waist and hip will be combined to report WHR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free androgen index (FAI) (%)</measure>
    <time_frame>5-week intervention period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total testosterone (TT) (ng/mL)</measure>
    <time_frame>5-week intervention period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) for insulin</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Insulin release test will be conducted</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) for glucose</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Glucose tolerance test will be conducted</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) for insulin/Area under the curve (AUC) for glucose</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Glucose tolerance test will be conducted</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting insulin (FINS) (mU/L)</measure>
    <time_frame>5-week intervention period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting blood glucose (FBG) (mmol/L)</measure>
    <time_frame>5-week intervention period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary behavior</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Measured by the Three Factor Eating Questionnaire Revised 21 Item (TFEQ-R21) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to normal menstrual cycle</measure>
    <time_frame>5-week intervention period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like growth factor 1 (IGF-1) (ng/mL)</measure>
    <time_frame>5-week intervention period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat (kg)</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Measured by InBody, a body composition analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat percentage (%)</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Measured by InBody, a body composition analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral fat area (cm^2)</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Measured by InBody, a body composition analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle content (kg)</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>Measured by InBody, a body composition analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive protein (hs-CRP) (mg/L)</measure>
    <time_frame>5-week intervention period</time_frame>
    <description>A kind of inflammatory biomarker</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Luteinizing hormone (LH) (mIU/mL)</measure>
    <time_frame>5-week intervention period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Follicle-stimulating hormone (FSH) (mIU/mL)</measure>
    <time_frame>5-week intervention period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>LH/FSH</measure>
    <time_frame>5-week intervention period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Uric acid (UA) (umol/L)</measure>
    <time_frame>5-week intervention period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Alanine aminotransferase (ALT) (U/L)</measure>
    <time_frame>5-week intervention period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Aspartate aminotransferase (AST) (U/L)</measure>
    <time_frame>5-week intervention period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total cholesterol (TC) (mmol/L)</measure>
    <time_frame>5-week intervention period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Triglycerides (TG) (mmol/L)</measure>
    <time_frame>5-week intervention period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Low density lipoprotein-cholesterol (LDL-C) (mmol/L)</measure>
    <time_frame>5-week intervention period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body weight (kg)</measure>
    <time_frame>5-week intervention period</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Time-Restricted Feeding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 16:8 TRF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Time-Restricted Feeding</intervention_name>
    <description>The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.&#xD;
Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day.</description>
    <arm_group_label>Time-Restricted Feeding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age ≥ 18 years; BMI≥24kg/m2; Anovulation; Rott-PCOS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Taking weight loss or regulate hormone secretion medications in recent 6 months; The body&#xD;
        weight fluctuated more than 5% in the past 3 months; Preparation for pregnancy, having been&#xD;
        in pregnancy or lactation; Perimenopausal; Night-shift workers; Fasting more than 16 hours&#xD;
        a day; Hypotension; Patients with other diseases (such as congenital adrenal hyperplasia,&#xD;
        Cushing syndrome, androgen-secreting tumors, hyperprolactinemia, diabetes, thyroid&#xD;
        diseases, severe serious cardiovascular, gastrointestinal, kidney or liver diseases);&#xD;
        Alcohol intake more than 100g per week; Smoking within 3 months; Engaging in high-intensity&#xD;
        exercise.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only women with PCOS.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing He, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shengjing hospital affiliated to China Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chunzhu Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shengjing hospital affiliated to China Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Chunzhu Li</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

